Health & Biotech

The Health sector index beat the ASX 200 in December But it underperformed the benchmark index over 2023 We take…

Reimbursement for minimally invasive glaucoma surgery in the US will stay intact This is good news for Nova's iTrack portfolio…

Recce Pharma announces further positive data on RECCE 327 Cynata says results from Phase 1 will be released in Q1…

People are reportedly quitting popular weight loss drugs Ozempic and Wegovy after 3 months Side effects such as loss of…

Part two of our series on ASX biotechs with upcoming catalysts in 2024 includes AI-focused medtech company Artrya (ASX:AYA).

Opthea up almost 10pc this morning after funding announcement Radiopharm to open second clinical trial site in Perth   Opthea…

Optiscan is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and…

Part one of our series on ASX biotechs with upcoming catalysts in 2024 includes market darling of 2023 Neuren Pharmaceuticals…

Next Science shares jump after publication of XPERIENCE on renowned journal. Radiopharm to commence Phase 1 trial.

FightMND, Australia’s leading not-for-profit foundation for motor neurone disease research, has invited PharmAust to submit a full grant application to…